Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1–10 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1
- Medicine slug
- abacavir
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
83%
- Numeric value
- 83
- Unit
- %
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
The geometric mean absolute bioavailability of the tablet was 83%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d791375-e311-41f9-87b8-940657e6318c (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
The geometric mean absolute bioavailability of the tablet was 83%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2214976-657c-4018-b059-1ad66a7e2b6f (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
The geometric mean absolute bioavailability of the tablet was 83%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2f06528-f3c5-2466-e053-2995a90ae18a (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
The geometric mean absolute bioavailability of the tablet was 83%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec9e2c36-b9b7-4ac2-a366-f3ad51237f28 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
The geometric mean absolute bioavailability of the tablet was 83%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42ca758a-1694-c614-e063-6294a90a8c7e (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
The geometric mean absolute bioavailability of the tablet was 83%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44fb1e25-ad03-4a7f-9f35-2e29f5025661 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
The geometric mean absolute bioavailability of the tablet was 83%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b286ec6-68a7-4ec0-af07-5a27ec9cb35d (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
The geometric mean absolute bioavailability of the tablet was 83%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7633480-25aa-4326-bec9-82835b486a20 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
The geometric mean absolute bioavailability of the tablet was 83%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5409c8ed-17c3-454f-bb88-d597ba8f84ec (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
The geometric mean absolute bioavailability of the tablet was 83%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca73b519-015a-436d-aa3c-af53492825a1 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
The geometric mean absolute bioavailability of the tablet was 83%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5cbf204-c10d-444b-aba0-180a30645d55 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
The geometric mean absolute bioavailability of the tablet was 83%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:633f1ec9-53b1-4a9a-a738-8cae5b763f08 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
The geometric mean absolute bioavailability of the tablet was 83%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01e46f58-8bda-4ff3-ab21-57d5b540d440 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
The geometric mean absolute bioavailability of the tablet was 83%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80c1702a-973c-436a-90f8-69b29674dca0 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
The geometric mean absolute bioavailability of the tablet was 83%.
Projected row 2
- Medicine slug
- abacavir
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
1.54 ± 0.63 hours
- Numeric value
- 1.54
- Unit
- hours
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Elimination In single-dose trials, the observed elimination half-life (t 1/2 ) was 1.54 ± 0.63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d791375-e311-41f9-87b8-940657e6318c (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Elimination: In single-dose trials, the observed elimination half-life (t½) was 1.54 ± 0.63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2214976-657c-4018-b059-1ad66a7e2b6f (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Elimination: In single-dose trials, the observed elimination half-life (t 1/2 ) was 1.54 ± 0.63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2f06528-f3c5-2466-e053-2995a90ae18a (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Elimination: In single-dose trails, the observed elimination half-life (t 1/2 ) was 1.54 ± 0.63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec9e2c36-b9b7-4ac2-a366-f3ad51237f28 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Elimination: In single-dose trials, the observed elimination half-life (t 1/2 ) was 1.54 ± 0.63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42ca758a-1694-c614-e063-6294a90a8c7e (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Elimination: In single-dose trails, the observed elimination half-life (t 1/2 ) was 1.54 ± 0.63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44fb1e25-ad03-4a7f-9f35-2e29f5025661 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Elimination: In single-dose trials, the observed elimination half-life (t 1/2 ) was 1.54 ± 0.63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b286ec6-68a7-4ec0-af07-5a27ec9cb35d (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Elimination: In single-dose trials, the observed elimination half-life (t 1/2 ) was 1.54 ± 0.63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7633480-25aa-4326-bec9-82835b486a20 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Elimination In single-dose trials, the observed elimination half-life (t 1/2 ) was 1.54 ± 0.63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5409c8ed-17c3-454f-bb88-d597ba8f84ec (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Elimination: In single-dose trials, the observed elimination half-life (t 1/2 ) was 1.54 ± 0.63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca73b519-015a-436d-aa3c-af53492825a1 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Elimination: In single-dose trials, the observed elimination half-life (t ½ ) was 1.54 ± 0.63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5cbf204-c10d-444b-aba0-180a30645d55 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Elimination: In single-dose trials, the observed elimination half-life (t ½ ) was 1.54 ± 0.63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:633f1ec9-53b1-4a9a-a738-8cae5b763f08 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Elimination: In single-dose trails, the observed elimination half-life (t 1/2 ) was 1.54 ± 0.63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01e46f58-8bda-4ff3-ab21-57d5b540d440 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Elimination: In single-dose trials, the observed elimination half-life (t 1/2 ) was 1.54 ± 0.63 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80c1702a-973c-436a-90f8-69b29674dca0 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Elimination In single-dose trials, the observed elimination half-life (t 1/2 ) was 1.54 ± 0.63 hours.
Projected row 3
- Medicine slug
- abacavir
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 15
- Source count
- 15
- Agreement rate
- 1
- Recorded readings
0.86 ± 0.15 L
- Numeric value
- 0.86
- Unit
- L
- Source records
- 15
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 15 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution after IV administration of abacavir was 0.86 ± 0.15 L per kg, suggesting that abacavir distributes into extravascular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0d791375-e311-41f9-87b8-940657e6318c (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of abacavir was 0.86 ± 0.15 L per kg, suggesting that abacavir distributes into extravascular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2214976-657c-4018-b059-1ad66a7e2b6f (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of abacavir was 0.86 ± 0.15 L per kg, suggesting that abacavir distributes into extravascular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2f06528-f3c5-2466-e053-2995a90ae18a (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of abacavir was 0.86 ± 0.15 L per kg, suggesting that abacavir distributes into extravascular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec9e2c36-b9b7-4ac2-a366-f3ad51237f28 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of abacavir was 0.86 ± 0.15 L per kg, suggesting that abacavir distributes into extravascular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42ca758a-1694-c614-e063-6294a90a8c7e (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of abacavir was 0.86 ± 0.15 L per kg, suggesting that abacavir distributes into extravascular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44fb1e25-ad03-4a7f-9f35-2e29f5025661 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of abacavir was 0.86 ± 0.15 L per kg, suggesting that abacavir distributes into extravascular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b286ec6-68a7-4ec0-af07-5a27ec9cb35d (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of abacavir was 0.86 ± 0.15 L per kg, suggesting that abacavir distributes into extravascular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7633480-25aa-4326-bec9-82835b486a20 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution after IV administration of abacavir was 0.86 ± 0.15 L per kg, suggesting that abacavir distributes into extravascular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5409c8ed-17c3-454f-bb88-d597ba8f84ec (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of abacavir was 0.86 ± 0.15 L per kg, suggesting that abacavir distributes into extravascular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca73b519-015a-436d-aa3c-af53492825a1 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of abacavir was 0.86 ± 0.15 L per kg, suggesting that abacavir distributes into extravascular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5cbf204-c10d-444b-aba0-180a30645d55 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of abacavir was 0.86 ± 0.15 L per kg, suggesting that abacavir distributes into extravascular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:633f1ec9-53b1-4a9a-a738-8cae5b763f08 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of abacavir was 0.86 ± 0.15 L per kg, suggesting that abacavir distributes into extravascular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01e46f58-8bda-4ff3-ab21-57d5b540d440 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Distribution: The apparent volume of distribution after IV administration of abacavir was 0.86 ± 0.15 L per kg, suggesting that abacavir distributes into extravascular space.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80c1702a-973c-436a-90f8-69b29674dca0 (opens source in a new tab)
Abacavir label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution after IV administration of abacavir was 0.86 ± 0.15 L per kg, suggesting that abacavir distributes into extravascular space.
Projected row 4
- Medicine slug
- abiraterone
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 31
- Source count
- 31
- Agreement rate
- 0.967742
- Recorded readings
12 ± 5 hours
- Numeric value
- 12
- Unit
- hours
- Source records
- 30
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 30 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba32c453-a231-452a-a6d9-b3e57afb2e75 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42d5baa8-aca7-49d8-9c24-9d87b707ec20 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79082b18-adde-4ffb-832a-b8c1d030c413 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68121a71-5024-4f9e-bd9c-2d412f6a6355 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patient with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e338e89-3cf2-48eb-b6e2-a06c608c6513 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39434b24-bf64-f5c9-fbb6-b0d225099424 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1200e4e-c4f7-9067-e053-2a95a90af509 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Excretion In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3e7f851-4132-4003-8f14-0eea21e5009c (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54ae5ef9-aea5-484a-a473-863b1397e206 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b36bff33-595e-4827-9a73-85c6954c314c (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fda6b92-59ed-4180-af68-94052a5e82cf (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:445e70a1-25bd-8fc1-e063-6394a90a1a43 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ef857ee-2bfc-4d27-a417-ad58fc3a6ff6 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7eda0d98-c2ba-c117-b757-1f566292e789 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f932015-28b2-4f44-ac04-772e982e13e9 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49809a29-6558-43a3-a347-5027de44aa41 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8967e10-f768-47ce-ac9e-2324c8390132 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ce9d926-ef3a-4b22-a703-f49c18eb4e3d (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:413c645e-074d-4276-b39a-d83521077602 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f5b628b-69da-4a04-a4d5-623b18d1fd5d (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours Metabolism Following oral administration of 14 C-abiraterone acetate as capsules, abiraterone acetate is hydrolyzed to abiraterone (active metabolite).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58b88e76-eba4-2471-e063-6394a90ad988 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be29365a-ed25-44c0-9818-e9016dc95ba6 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ac063f0-4177-c90f-27c3-e70e29689255 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f82d549-6654-1efd-e053-2991aa0aa28d (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Excretion In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f308b463-27e4-422a-95a2-ecbbf95eee20 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe02db79-fa04-441f-b514-70bd74af6624 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c91aa38-3b0a-232c-8eb1-55f08e8e6644 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5108c2fe-9706-c976-e063-6294a90a796d (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88d05db3-8bdc-47f1-bb00-6b4a71f98609 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours Metabolism Following oral administration of 14 C-abiraterone acetate as capsules, abiraterone acetate is hydrolyzed to abiraterone (active metabolite).
18 hours
- Numeric value
- 18
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32f6b83d-c743-4934-9a20-1b5bf9f4eea3 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The mean half-life of abiraterone is prolonged to approximately 18 hours in subjects with mild hepatic impairment and to approximately 19 hours in subjects with moderate hepatic impairment.
Projected row 5
- Medicine slug
- abiraterone
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 31
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
99%
- Numeric value
- 99
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1200e4e-c4f7-9067-e053-2a95a90af509 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Distribution and Protein Binding Abiraterone is highly bound (>99%) to the human plasma proteins, albumin and alpha-1 acid glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f82d549-6654-1efd-e053-2991aa0aa28d (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
Distribution and Protein Binding Abiraterone is highly bound (>99%) to the human plasma proteins, albumin and alpha-1 acid glycoprotein.
Projected row 6
- Medicine slug
- abiraterone
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 31
- Source count
- 31
- Agreement rate
- 1
- Recorded readings
19,669 ± 13,358 L
- Numeric value
- 19,669
- Unit
- L
- Source records
- 31
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 31 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba32c453-a231-452a-a6d9-b3e57afb2e75 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42d5baa8-aca7-49d8-9c24-9d87b707ec20 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32f6b83d-c743-4934-9a20-1b5bf9f4eea3 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79082b18-adde-4ffb-832a-b8c1d030c413 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68121a71-5024-4f9e-bd9c-2d412f6a6355 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e338e89-3cf2-48eb-b6e2-a06c608c6513 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39434b24-bf64-f5c9-fbb6-b0d225099424 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1200e4e-c4f7-9067-e053-2a95a90af509 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3e7f851-4132-4003-8f14-0eea21e5009c (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54ae5ef9-aea5-484a-a473-863b1397e206 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b36bff33-595e-4827-9a73-85c6954c314c (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fda6b92-59ed-4180-af68-94052a5e82cf (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:445e70a1-25bd-8fc1-e063-6394a90a1a43 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ef857ee-2bfc-4d27-a417-ad58fc3a6ff6 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7eda0d98-c2ba-c117-b757-1f566292e789 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f932015-28b2-4f44-ac04-772e982e13e9 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49809a29-6558-43a3-a347-5027de44aa41 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8967e10-f768-47ce-ac9e-2324c8390132 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ce9d926-ef3a-4b22-a703-f49c18eb4e3d (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:413c645e-074d-4276-b39a-d83521077602 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f5b628b-69da-4a04-a4d5-623b18d1fd5d (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58b88e76-eba4-2471-e063-6394a90ad988 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be29365a-ed25-44c0-9818-e9016dc95ba6 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ac063f0-4177-c90f-27c3-e70e29689255 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f82d549-6654-1efd-e053-2991aa0aa28d (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f308b463-27e4-422a-95a2-ecbbf95eee20 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe02db79-fa04-441f-b514-70bd74af6624 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c91aa38-3b0a-232c-8eb1-55f08e8e6644 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5108c2fe-9706-c976-e063-6294a90a796d (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88d05db3-8bdc-47f1-bb00-6b4a71f98609 (opens source in a new tab)
Abiraterone label
Version not recorded · Effective date not recorded
The apparent steady-state volume of distribution (mean ± SD) is 19,669 ± 13,358 L.
Projected row 7
- Medicine slug
- abrocitinib
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
60%
- Numeric value
- 60
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16c12a56-4550-414b-ac9d-b785b41fea6b (opens source in a new tab)
Abrocitinib label
Version not recorded · Effective date not recorded
Absorption Abrocitinib is absorbed with over 91% extent of oral absorption and absolute oral bioavailability of approximately 60%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f6d6fcd-e9f9-42c8-bfa2-bb2cfc9ed258 (opens source in a new tab)
Abrocitinib label
Version not recorded · Effective date not recorded
Absorption Abrocitinib is absorbed with over 91% extent of oral absorption and absolute oral bioavailability of approximately 60%.
Projected row 8
- Medicine slug
- abrocitinib
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16c12a56-4550-414b-ac9d-b785b41fea6b (opens source in a new tab)
Abrocitinib label
Version not recorded · Effective date not recorded
The peak plasma concentrations of abrocitinib are reached within 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f6d6fcd-e9f9-42c8-bfa2-bb2cfc9ed258 (opens source in a new tab)
Abrocitinib label
Version not recorded · Effective date not recorded
The peak plasma concentrations of abrocitinib are reached within 1 hour.
Projected row 9
- Medicine slug
- abrocitinib
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
100 L
- Numeric value
- 100
- Unit
- L
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16c12a56-4550-414b-ac9d-b785b41fea6b (opens source in a new tab)
Abrocitinib label
Version not recorded · Effective date not recorded
Distribution After intravenous administration, the volume of distribution of abrocitinib is approximately 100 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f6d6fcd-e9f9-42c8-bfa2-bb2cfc9ed258 (opens source in a new tab)
Abrocitinib label
Version not recorded · Effective date not recorded
Distribution After intravenous administration, the volume of distribution of abrocitinib is approximately 100 L.
Projected row 10
- Medicine slug
- acalabrutinib
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
25%
- Numeric value
- 25
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1409184-3267-4d8c-8f17-4e01f69828b1 (opens source in a new tab)
Acalabrutinib label
Version not recorded · Effective date not recorded
Absorption The geometric mean absolute bioavailability of acalabrutinib was 25%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd4835ef-e1bc-4997-a399-1ffa2556fbfe (opens source in a new tab)
Acalabrutinib label
Version not recorded · Effective date not recorded
Absorption The geometric mean absolute bioavailability of acalabrutinib was 25%.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.